William Blair Analysts Name Carterra a Winner in Life Science Tools for Enabling AI Drug Discovery at Unprecedented Scale
William Blair Analysts Name Carterra a Winner in Life Science Tools for Enabling AI Drug Discovery at Unprecedented Scale
Carterra, with its HT-SPR technology platforms, is listed alongside large public companies as a technology provider to capitalize on the likely growth in wet lab work driven by the increasing use of AI in early discovery
Salt Lake City, Utah, 8th April, 2026: William Blair analysts Matthew Larew and Jacob Krahenbuhl published a white paper this week entitled, “From Code to Clinic: How AI Is (and Isn’t) Rewriting the Life of a Drug”1. As part of their analysis, they asserted that wet lab experiments will likely increase as the use of AI permeates drug discovery workflows and labeled Carterra a “Winner” in providing novel technology in the following categories:
- Antigen and Assay Preparation
- Hit ID/Antibody Preparation/Primary Screening
- Binding and Characterization
- Antibody Engineering and Optimization
Read the Press Release